Clinical-stage Houston cell therapy company closes $28.4M oversubscribed series A

cha-ching

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. Photo via Getty Images

An emerging biotech company in Houston has closed its series A with outsized success.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The company has now raised more than $51 million in total.

Last year, March Biosciences announced its strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. CEO Sarah Hein met her co-founder, Max Mamonkin, at the TMC Accelerator for Cancer Therapeutics. Along with fellow co-founder Malcolm Brenner, March Biosciences launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital). Its goal is to fight cancers that have been unresponsive to existing immunotherapies using its lead asset, MB-105.

An autologous CD5-targeted CAR-T cell therapy, MB-105 is currently in phase-1 trials in patients with refractory T-cell lymphoma and leukemia. The treatment is showing signs of being both safe and effective, meriting a phase-2 trial that will begin early next year. The funds raised from the series A will help to finance the Phase 2 clinical development of MB-105 to expand on the existing data with optimized manufacturing processes.

“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” says Hein. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”

But that’s not the only exciting news that Hein and her associates have to report. March Biosciences has recently partnered with cell therapy venture studio, Volnay Therapeutics. Led by highly experienced cell therapy development veterans, the March Biosciences team will work to develop a scalable manufacturing process for MB-105 that will lead to commercialization. Volnay co-founder and CEO Stefan Wildt, who held key R&D leadership positions in cell and gene therapy units at Novartis and Takeda, has also joined the board of March Biosciences. The board of directors is also welcoming Cassidy Blundell of Mission BioCapital and Owen Smith of 4BIO Capital.

“The team at March Biosciences is leveraging powerful science and promising clinical data to tackle cancers with significant unmet need,” says Blundell, a partner at Mission BioCapital. “We're excited to support their journey and believe their focused approach with MB-105 could lead to significant breakthroughs in the CAR-T space.”

The Houston-born company, which is a finalist for the 2024 Houston Innovation Awards, continues to accelerate quickly, in part thanks to its home base. After all, existing local investors like TMC Venture Fund also participated in the new raise. As Hein said last year, “Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

From Your Site Articles
CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

CPRIT funding spotted

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Aside from the grant, OncoResponse just hauled in $14 million from existing investors in a round led by RiverVest Venture Partners. Other participants in the series D round include Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, and InterVest Capital Partners.

To date, OncoResponse has raised more than $180 million, according to market research company CB Insights.

A representative of OncoResponse couldn’t be reached for comment about the company’s relocation to Houston.

MD Anderson and Seattle-based Theraclone Sciences launched OncoResponse in 2015. Rice University was among the inaugural investors.

OncoResponse’s OR2805 immunotherapy product is being evaluated in a Phase 1 clinical trial. It’s the company’s leading immunotherapy candidate. OncoResponse is also working on OR502, an antibody being prepared for investigational and clinical studies.

“The modern treatment of cancer activates the body’s own immune system to attack cancer,” OncoResponse says in a summary posted on the website of the Cancer Prevention and Research Institute of Texas (CPRIT).

“These treatments, called immunotherapy, may not be successful if the cancer can recruit bad-acting cells, such as tumor associated macrophages, or TAMs, that create barriers preventing immunotherapies from activating the body’s own defenses against the cancer. To find drugs that may help counteract these TAMs, OncoResponse looked to patients who had responded very well to immunotherapy to see if their bodies made factors to block TAMs and helped them fight their cancers.”

OncoResponse’s OR502 prevents TAMs from shutting down the body’s response to cancer, thus restoring tumor-killing immune activity, CPRIT explains.

In addition to OncoResponse, recent CPRIT grant recipients from the Houston area are:

  • Houston-based 7 Hills Pharma, $13,439,001. The company is working on immunotherapies for treatment of cancer and prevention of infectious diseases.
  • Houston-based Allterum Therapeutics, $11,721,150. The company is coming up with an antibody for treatment of patients with acute lymphoblastic leukemia. This type of cancer affects blood and bone marrow.
  • Houston-based Cell Therapy Manufacturing Center, $9.1 million. The center is a joint venture between National Resilience and MD Anderson Cancer Center that is developing cell therapy manufacturing technologies to support biotech partnerships.
  • Houston-based Pulmotect, $8,851,165. The company’s PUL-042 product is aimed at treating and preventing respiratory complications in cancer patients.
  • Cancer researcher Michael King, $6 million. The grant helped lure King to Rice from Nashville’s Vanderbilt University, where he’s been the chair of biomedical engineering. King’s lab at Vanderbilt has been testing therapies for metastatic breast cancer and prostate cancer.
  • Missouri City-based OmniNano Pharmaceuticals, $2,711,437. The pharmatech company is working on two drugs for treatment of solid tumors in patients with pancreatic cancer.

“Texas is unique because of CPRIT’s ability to invest in cutting-edge research when private capital is scarce. This is yet another way Texas is leading the nation in the fight against cancer,” Wayne Roberts, CEO of CPRIT, says in a news release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston space tech companies land $25 million from Texas commission

Out Of This World

Two Houston aerospace companies have collectively received $25 million in grants from the Texas Space Commission.

Starlab Space picked up a $15 million grant, and Intuitive Machines gained a $10 million grant, according to a Space Commission news release.

Starlab Space says the money will help it develop the Systems Integration Lab in Webster, which will feature two components — the main lab and a software verification facility. The integration lab will aid creation of Starlab’s commercial space station.

“To ensure the success of our future space missions, we are starting with state-of-the-art testing facilities that will include the closest approximation to the flight environment as possible and allow us to verify requirements and validate the design of the Starlab space station,” Starlab CEO Tim Kopra said in a news release.

Starlab’s grant comes on top of a $217.5 million award from NASA to help eventually transition activity from the soon-to-be-retired International Space Station to new commercial destinations.

Intuitive Machines is a space exploration, infrastructure and services company. Among its projects are a lunar lander designed to land on the moon and a lunar rover designed for astronauts to travel on the moon’s surface.

The grants come from the Space Commission’s Space Exploration and Aeronautics Research Fund, which recently awarded $47.7 million to Texas companies.

Other recipients were:

  • Cedar Park-based Firefly Aerospace, which received $8.2 million
  • Brownsville-based Space Exploration Technologies (SpaceX), which received $7.5 million
  • Van Horn-based Blue Origin, which received $7 million

Gwen Griffin, chair of the commission, says the grants “will support Texas companies as we grow commercial, military, and civil aerospace activity across the state.”

State lawmakers established the commission in 2023, along with the Texas Aerospace Research & Space Economy Consortium, to bolster the state’s space industry.

Houston experts: Can AI bridge the gap between tech ambitions and market realities?

guest column

Despite successful IPOs from the likes of Ibotta, Reddit and OneStream, 2024 hasn’t provided the influx of capital-raising opportunities that many late-stage tech startups and venture capitalists (VCs) have been waiting for. Since highs last seen in 2021—when 90 tech companies went public—the IPO market has been effectively frozen, with just five tech IPOs between January and September 2024.

As a result, limited partners have not been able to replenish investments and redeploy capital. This shifting investment landscape has VCs and tech leaders feeling stuck in a holding pattern. Tech leaders are hesitant to enter the public markets because valuations are down 30 percent to 40 percent from 2021, which is also making late-stage fundraising more challenging. After all, longer IPO timelines mean fewer exit opportunities for VCs and reduced capital from institutional investors who are turning toward shorter-term investments with more liquid exit options.

Of course, there’s always an exception. And in the case of a slowed IPO market, a select slice of tech companies—AI-related companies—are far outperforming others. While not every tech startup has AI software or infrastructure as their core offering, most can benefit from using AI to revise their playbook and become more attractive to investors.

Unlocking Growth Potential with AI

While overall tech startup investment has slowed, the AI sector burns bright. This presents an opportunity for companies that strategically leverage AI, not just as a buzzword but as a tool for genuine growth and differentiation. Imagine a future where AI-powered insights unlock unprecedented efficiency, customer engagement and a paradigm shift in value creation. This isn’t just about weathering the current storm of reduced access to capital; it’s about emerging stronger, ready to lead the next wave of tech innovation.

Here's how to navigate the AI frontier and unlock its potential:

  1. Understand that data is the foundation of AI success. AI is powerful, but it’s not magic. It thrives on high-quality, interconnected data. Before diving into AI initiatives, companies must assess their data health. Is it structured in a way that AI can understand? Does it go beyond raw numbers to capture context and meaning—like customer sentiment alongside sales figures? Rethinking data infrastructure is often the crucial first step.
  1. Focus on amplifying strengths, not reinventing the wheel. The allure of AI can tempt companies into pursuing radical reinvention. However, a more effective strategy is to leverage AI to enhance existing strengths and address core customer needs. Why do customers choose your company? How can AI supercharge your value proposition? Consider Reddit’s strategic approach: They didn’t overhaul their platform before their 2024 IPO. Instead, they showcased the value of their vast online communities as fertile ground for AI development, leading to a remarkable first-day stock surge of 48 percent.

  2. Use AI as a customer-centric force multiplier. Companies with a deep understanding of their customer base are primed for AI success. By integrating AI into the very core of their product or service—the reason customers choose them—they can create a decisive competitive advantage based on delivering tangible customer value.

From Incremental Gains to Transformative Growth

This practical, customer-centric approach has the potential to help companies generate immediate growth while laying the foundation for future reinvention. By leveraging AI to optimize operations, deepen customer relationships, and redefine industry paradigms, late-state tech startups can not only survive but thrive in a dynamic market. The future belongs to those who embrace AI not as a destination but as a continuous journey of innovation and growth.

------

Hong Ogle is the president of Bank of America Houston. Rodrigo Ortiz Gomez is a market executive in Bank of America’s Transformative Technology Banking Group as well as the national software banking lead for the Global Commercial Bank.

Houston joint venture secures $5.2M for AI-powered methane tracking tech

Fresh Funds

Houston-based Envana Software Solutions has received more than $5.2 million in federal and non-federal funding to support the development of technology for the oil and gas sector to monitor and reduce methane emissions.

Thanks to the work backed by the new funding, Envana says its suite of emissions management software will become the industry's first technology to allow an oil and gas company to obtain a full inventory of greenhouse gases.

The funding comes from a more than $4.2 million grant from the U.S. Department of Energy (DOE) and more than $1 million in non-federal funding.

“Methane is many times more potent than carbon dioxide and is responsible for approximately one-third of the warming from greenhouse gases occurring today,” Brad Crabtree, assistant secretary at DOE, said in 2024.

With the funding, Envana will expand artificial intelligence (AI) and physics-based models to help detect and track methane emissions at oil and gas facilities.

“We’re excited to strengthen our position as a leader in emissions and carbon management by integrating critical scientific and operational capabilities. These advancements will empower operators to achieve their methane mitigation targets, fulfill their sustainability objectives, and uphold their ESG commitments with greater efficiency and impact,” says Nagaraj Srinivasan, co-lead director of Envana.

In conjunction with this newly funded project, Envana will team up with universities and industry associations in Texas to:

  • Advance work on the mitigation of methane emissions
  • Set up internship programs
  • Boost workforce development
  • Promote environmental causes

Envana, a software-as-a-service (SaaS) startup, provides emissions management technology to forecast, track, measure and report industrial data for greenhouse gas emissions.

Founded in 2023, Envana is a joint venture between Houston-based Halliburton, a provider of products and services for the energy industry, and New York City-based Siguler Guff, a private equity firm. Siguler Gulf maintains an office in Houston.

“Envana provides breakthrough SaaS emissions management solutions and is the latest example of how innovation adds to sustainability in the oil and gas industry,” Rami Yassine, a senior vice president at Halliburton, said when the joint venture was announced.

---

This story originally appeared on our sister site, EnergyCapitalHTX.com

View All Listings